By Dani Kass ( January 22, 2020, 6:18 PM EST) -- A Bristol-Myers Squibb subsidiary and Memorial Sloan Kettering Cancer Center have asked a California federal judge to more than double a jury's $752 million patent infringement verdict against a Gilead unit for its cancer treatment Yescarta, saying the company must be punished for its "undisputed willfulness."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.